Mizuho Starts Coverage on Tarsus Pharmaceuticals With Bullish $100 Target

Mizuho initiates coverage on Tarsus Pharmaceuticals with an Outperform rating and a $100 price target, citing strong prospects for Xdemvy and projected peak sales above $2B.